SB 200646 hydrochloride
Biological Activity
5-HT2C/2B receptor antagonist, selective over 5-HT1A. Affinities are 7.4 (pA2), 6.9 (pKi) and 5.2 (pKi) for 5-HT2B, 2C and 2A respectively. Orally active in vivo.
Licensing Information
Sold under license
Compound Libraries
SB 200646 hydrochloride is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.
Technical Data
| M. Wt | 302.76 |
| Formula | C15H14N4O.HCl |
| Storage | Store at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 143797-62-0 |
| PubChem ID | 5311422 |
| InChI Key | IGRYPUQJEDJLHC-UHFFFAOYSA-N |
| Smiles | Cl.CN1C=CC2=CC(NC(=O)NC3=CN=CC=C3)=CC=C12 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 30.28 | 100 |
Preparing Stock Solutions
The following data is based on the product molecular weight 302.76. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.3 mL | 16.51 mL | 33.03 mL |
| 5 mM | 0.66 mL | 3.3 mL | 6.61 mL |
| 10 mM | 0.33 mL | 1.65 mL | 3.3 mL |
| 50 mM | 0.07 mL | 0.33 mL | 0.66 mL |
Molarity Calculator
Reconstitution Calculator
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Forbes et al (1993) N-(1-Methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT1C receptor antagonist. J.Med.Chem. 36 1104 PMID: 8478907
Kennett et al (1994) In vivo properties of SB 200646A, a 5-HT2C/2B recepor antagonist. Br.J.Pharmacol. 111 797 PMID: 7912626
Kennett et al (1995) Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology (Berl.) 118 178 PMID: 7617805
If you know of a relevant reference for SB 200646 hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: 5-HT2C/2B antagonists Serotonin 5-HT2B Receptors SB200646 hydrochloride 5-HT2C Receptors
1 Citation for SB 200646 hydrochloride
Citations are publications that use Tocris products. Selected citations for SB 200646 hydrochloride include:
Xiao et al (2008) Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling. Am J Physiol Endocrinol Metab 4 12 PMID: 18416824
Do you know of a great paper that uses SB 200646 hydrochloride from Tocris? If so please let us know.
Literature in this Area
GPCR Product Listing
A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:
- Rhodopsin-like Receptors
- Secretin-like Receptors
- Glutamate Receptors
- Frizzled Receptors
- GPCR Signaling
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
